ALNY

ALNYLAM PHARMACEUTICALS, INC.

ALNY · CIK 1178670 · Annual (10-K) · Last 8 years

Financial Trends

Revenue$3.7B
20182025
Net Income$0.3B
20182025
Operating CF$0.5B
20182025
Free Cash Flow$0.5B
20182025

Income Statement

MetricFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Revenue$3.7B$2.2B$1.8B$1.0B$0.8B$0.2B$0.1B$0.0B
Cost of Revenue$0.7B$0.3B$0.3B$0.1B$0.1B$0.1B$0.0B$0.0B
Gross Profit
R&D Expense$1.3B$1.1B$1.0B$0.9B$0.8B$0.7B$0.7B$0.5B
SG&A Expense$1.2B$1.0B$0.8B$0.8B$0.6B$0.6B$0.5B$0.4B
Operating Income$0.5B$-0.2B$-0.3B$-0.8B$-0.7B$-0.8B$-0.9B$-0.8B
Net Income$0.3B$-0.3B$-0.4B$-1.1B$-0.9B$-0.2B$-0.3B$-0.2B
EPS (Basic)$2.39$-2.18$-3.52$-9.30$-7.20
EPS (Diluted)$2.33$-2.18$-3.52$-9.30$-7.20

Balance Sheet

MetricFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Total Assets$5.0B$4.2B$3.8B$3.5B$3.6B$3.4B$2.4B$1.6B
Current Assets$4.1B$3.3B$3.0B$2.7B$2.8B$2.6B$1.7B$1.2B
Cash & Equivalents$1.7B$1.0B$0.8B$0.9B$0.8B$0.5B$0.5B$0.4B
Total Liabilities$4.2B$4.2B$4.1B$3.7B$3.1B$2.4B$1.0B$0.3B
Current Liabilities$1.5B$1.2B$1.0B$0.8B$0.7B$0.6B$0.4B$0.2B
Stockholders' Equity$0.8B$0.1B$-0.2B$-0.2B$0.6B$1.0B$1.4B$1.3B

Cash Flow Statement

MetricFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Operating Cash Flow$0.5B$-0.0B$0.1B$-0.5B$-0.6B$-0.6B$-0.3B$-0.6B
Investing Cash Flow$0.4B$-0.1B$-0.3B$0.2B$-0.3B$-0.4B$-0.4B$0.3B
Capital Expenditures$0.1B$0.0B$0.1B$0.1B$0.1B$0.1B$0.1B$0.1B
Financing Cash Flow$-0.3B$0.3B$0.2B$0.4B$1.2B$1.0B$0.8B$0.1B